Abera Bioscience improved its financial position in 2024, driven by major grants, cost control, and strong preclinical vaccine results. The company secured funding for at least 12 months and advanced its pipeline in mucosal and pandemic vaccines.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.